Despite immune checkpoint blockade's unnoticed effectiveness in providing certain non-small-cell lung cancer NSCLC patients with long-lasting responses, the majority of patients do not react. There ... response rates to…
Background: Immune Checkpoint Inhibitors (ICIs) administered in first-line monotherapy are the standard treatment for patients with Non-Small-Cell Lung Cancer (NSCLC) and a high expression of Programmed Cell
reputation of checkpoint inhibitors as potential game changers in oncology is well-deserved as the the 14/14 complete responses recently reported with the PD-1 inhibitor, dostarlimab, in mismatch ... mimic the…
using viruses to fight cancer cells. When immunotherapy in the form of immune checkpoint inhibitors has made significant advances in the clinical practice of lung cancer, the induction of antitumor
Immune checkpoint inhibitor immunotherapy has transformed the treatment of Non-Small Cell Lung Cancer (NSCLC). Although monoclonal antibodies against programmed cell death-1 (PD-1) and PD ligand
Background: Immune Checkpoint Inhibitors (ICIs) cause ICI-related Adverse Events (irAEs) such as dry eye and uveitis, which can be severe, sometimes necessitating the suspension of ICI treatment. Retrospective studies
same individual. Also, the correlation between the expression levels of the five main immune checkpoints genes and the count of TCR clones displayed various among different types of cancers. Conclusion
immune system by failing to recognize tumor antigens by host cells. Certain immune checkpoints have been observed while performing immunotherapy. These immune checkpoints show immune resistance especially for T cells…
year-old woman who presented with liver damage after receiving immune checkpoints inhibitors (ICIs). At age 55 years, the patient was diagnosed with limited cutaneous systemic sclerosis; tests for antinuclear
Background: Immune Checkpoint Inhibitors (CPIs) have been proven to be effective in terms of the response rate and survival of cancer patients. However, these drugs are responsible for several immune
Pembrolizumab is an Immune Checkpoint Inhibitor (ICI) that exerts anti-tumor activity by inhibiting the interaction of programmed cell death protein 1 with its ligand (PD-L1) on activated lymphocytes.Immune
immune checkpoint inhibitors in cancer therapy increases across a wide range of tumor types, rarer toxicities including rheumatologic immune adverse events are reported with increasing frequency. We describe the case
selectively considered. Recently, it has been suggested that the use of Immune Checkpoint Inhibitors (ICIs) prior to CN could be associated with increased fibrosis and adhesions in and around
biomarker was examined in the previous study. Twenty-nine patients treated with immune checkpoint inhibitors were divided into three groups according to their IFN-γ release level in the positive
Introduction: Immune checkpoint inhibitors (ICIs) are revolutionizing cancer therapy and have significantly improved the clinical outcome of multiple tumor types. ICIs-induced myocarditis is a rare, but potential fatal…
potential role of the gut microbiomes in the response and toxicity to immune checkpoint inhibitor therapies (ICIs) in advanced malignancies has been a growing area of interest within the field
management of cancer patients with the approval of molecularly targeted agents and immune checkpoint inhibitors for a variety of malignancies. Further, in 2017, we saw the advent ... indicated. Acute interstitial…
cell lymphoma and 4T1 breast carcinoma with DOXHYD-HPMA and with immune checkpoint blocking anti-CTLA-4 and anti-PD-1 MAbs either alone or in a mixture. To document ... toxicity while significant co-toxicity was seen in…
programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) immune checkpoint modulates activated T cell-cancer cell interactions. The PD-L1 protein generated by tumor cells engages T lymphocyte ... desirable to seek non-immunologic…
anticancer therapies such as radiation and chemotherapy. Several other immunotherapeutic platforms, such as immune checkpoint inhibitors and DNA- and peptide-based vaccines are also in development and clinical testing…
Phase III clinical trials – one, ipilimumab, a monoclonal antibody against CTLA-4, a checkpoint inhibitor, and the other, Sipuleucel-T, an autologous-based cellular therapy. Ipilimumab is the second drug
programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-cancer cell interactions, serving to defend tumor cells against host immune destruction. Nano ... mechanism, endogenous T4…
activity was accessed by cell proliferation assay. The expression of molecules relevant to immune checkpoints were analyzed by real-time PCR using human gastric cancer cell lines; MKN1, MKN45
These molecules include antigen presenting molecules, adhesion molecules, co-stimulatory molecules, and inhibitors or checkpoint molecules, etc. The spatial and temporal changes of these molecules determine the…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.